Full name
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Multinational Study to Assess the Efficacy and Safety of Orally Administered Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenously Administered Imipenem-cilastatin in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (PIVOT-PO)
NCT Number
NCT06059846
Geography
US
Non-US
Locations
Argentina, Bosnia and Herzegovina,Bulgaria, Croatia, Estonia, Georgia,Hungary, Republic of Moldova, Poland,Romania, Serbia, Slovakia, South Africa,Turkey, United States
Primary Endpoints
Number of Participants With Overall Response at the Test-of-Cure (TOC) Visit. Day 17
External Link
https://clinicaltrials.gov/study/NCT06059846
Order
1
Disease
Version
Phase
3